Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Reduced-dose treatment with androgen receptor pathway inhibitors (ARPI) lead to poorer oncological outcomes relative to full-dose regimens in castration-resistant prostate cancer (CRPC), a recent study has found.

Dose-reduced ARPI leads to inferior survival in CRPC patients

09 Nov 2021

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

09 Nov 2021

Venetoclax with low-dose cytarabine safe, effective for untreated AML

In patients with untreated acute myeloid leukaemia (AML) ineligible for intensive chemotherapy, the combination of venetoclax with low-dose cytarabine (+LDAC) may be a safe and effective treatment option, inducing high rates of response and reducing mortality risk, a recent study has found.

Venetoclax with low-dose cytarabine safe, effective for untreated AML

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases

Concomitant administration of the human epidermal growth factor receptor 2 (HER2)–targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) with the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole appears to be safe and does not produce a clinically meaningful change in the pharmacokinetics of T-DXd or DXd, according to a phase I study.

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer

Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer

08 Nov 2021

Phase III study CONFIRMs nivolumab potential for mesothelioma treatment

08 Nov 2021 bởi

The anti-PD-1 antibody nivolumab demonstrated potential as a treatment alternative for relapsed malignant mesothelioma that has progressed following first-line chemotherapy (CT), the phase III CONFIRM* trial has shown.

Phase III study CONFIRMs nivolumab potential for mesothelioma treatment

Paclitaxel HIPEC safe, effective in adenocarcinoma of oesophagogastric junction

Hyperthermic intraperitoneal chemotherapy (HIPEC) improves postoperative cellular immune function in patients with adenocarcinoma of the oesophagogastric junction (AEG), a recent study has found.

Paclitaxel HIPEC safe, effective in adenocarcinoma of oesophagogastric junction

Excision of ocular surface neoplasia with 2-mm margins yields low recurrence rates

Excision of ocular surface squamous neoplasia (OSSN) with a 2-mm margin does not lead to high rates of positive surgical margins, a recent study has found. For patients who do show positive margins, adjuvant topical therapy is enough to prevent recurrence.

Excision of ocular surface neoplasia with 2-mm margins yields low recurrence rates

Transarterial infusion chemotherapy, microsphere embolization effective for gastroesophageal cancer

Transarterial infusion chemotherapy with microsphere embolization is an effective treatment option for gastroesophageal junction cancer with hepatic metastasis, a recent study has found.

Transarterial infusion chemotherapy, microsphere embolization effective for gastroesophageal cancer